Regenxbio Research Development vs Reconciled Depreciation Analysis

RGNX Stock

USD 9.92 0.09 0.90%

Regenxbio financial indicator trend analysis is much more than just breaking down Regenxbio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regenxbio is a good investment. Please check the relationship between Regenxbio Research Development and its Reconciled Depreciation accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.

Research Development vs Reconciled Depreciation

Research Development vs Reconciled Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regenxbio Research Development account and Reconciled Depreciation. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Regenxbio's Research Development and Reconciled Depreciation is 0.92. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Regenxbio, assuming nothing else is changed. The correlation between historical values of Regenxbio's Research Development and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Regenxbio are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Research Development i.e., Regenxbio's Research Development and Reconciled Depreciation go up and down completely randomly.

Correlation Coefficient

0.92

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Research Development

Reconciled Depreciation

Most indicators from Regenxbio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regenxbio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.Sales General And Administrative To Revenue is likely to rise to 1.49 in 2024, whereas Selling General Administrative is likely to drop slightly above 47.8 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	418.5M	58.2M	53.0M	91.4M
Total Revenue	470.3M	112.7M	90.2M	111.6M

Gross Profit Total Revenue

Regenxbio fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Non Currrent Assets Other	Other Assets	Short Term Investments	Inventory
Total Assets		0.86	0.84	0.83	0.96	0.75	-0.58	-0.54	0.71	0.79	0.95	0.96	0.84	-0.63	0.89	0.75	0.92	0.89	0.96	0.53	-0.63	0.95	0.68	0.61	0.68	0.89
Short Long Term Debt Total	0.86		0.95	0.94	0.7	0.45	-0.33	-0.75	0.87	0.64	0.83	0.79	0.78	-0.47	0.79	0.88	0.87	0.98	0.81	0.76	-0.47	0.78	0.39	0.43	0.59	0.91
Other Current Liab	0.84	0.95		1.0	0.72	0.46	-0.22	-0.83	0.92	0.55	0.83	0.77	0.74	-0.48	0.8	0.98	0.86	0.9	0.79	0.84	-0.48	0.8	0.44	0.46	0.6	0.98
Total Current Liabilities	0.83	0.94	1.0		0.71	0.45	-0.18	-0.85	0.94	0.51	0.82	0.76	0.73	-0.49	0.8	0.98	0.86	0.89	0.78	0.86	-0.49	0.8	0.43	0.42	0.63	0.97
Total Stockholder Equity	0.96	0.7	0.72	0.71		0.82	-0.55	-0.43	0.6	0.72	0.92	0.93	0.76	-0.67	0.86	0.65	0.87	0.73	0.93	0.42	-0.67	0.96	0.77	0.6	0.69	0.81
Current Deferred Revenue	0.75	0.45	0.46	0.45	0.82		-0.5	-0.17	0.34	0.57	0.74	0.7	0.69	-0.59	0.69	0.36	0.67	0.5	0.7	0.14	-0.59	0.74	0.46	0.59	0.5	0.56
Net Debt	-0.58	-0.33	-0.22	-0.18	-0.55	-0.5		-0.2	0.07	-0.93	-0.48	-0.63	-0.53	0.29	-0.35	-0.07	-0.32	-0.51	-0.61	0.26	0.29	-0.42	-0.33	-0.62	0.02	-0.29
Retained Earnings	-0.54	-0.75	-0.83	-0.85	-0.43	-0.17	-0.2		-0.93	-0.14	-0.46	-0.54	-0.55	0.48	-0.68	-0.88	-0.73	-0.63	-0.56	-0.97	0.48	-0.6	-0.3	0.04	-0.66	-0.81
Accounts Payable	0.71	0.87	0.92	0.94	0.6	0.34	0.07	-0.93		0.28	0.67	0.66	0.64	-0.49	0.76	0.91	0.83	0.77	0.68	0.95	-0.49	0.7	0.41	0.12	0.74	0.88
Cash	0.79	0.64	0.55	0.51	0.72	0.57	-0.93	-0.14	0.28		0.7	0.81	0.73	-0.41	0.58	0.41	0.58	0.78	0.81	0.09	-0.41	0.64	0.42	0.67	0.2	0.59
Non Current Assets Total	0.95	0.83	0.83	0.82	0.92	0.74	-0.48	-0.46	0.67	0.7		0.83	0.7	-0.53	0.8	0.76	0.85	0.84	0.84	0.5	-0.53	0.91	0.58	0.73	0.57	0.86
Cash And Short Term Investments	0.96	0.79	0.77	0.76	0.93	0.7	-0.63	-0.54	0.66	0.81	0.83		0.88	-0.67	0.9	0.66	0.9	0.84	1.0	0.49	-0.67	0.92	0.74	0.45	0.71	0.84
Net Receivables	0.84	0.78	0.74	0.73	0.76	0.69	-0.53	-0.55	0.64	0.73	0.7	0.88		-0.5	0.8	0.63	0.82	0.83	0.9	0.49	-0.5	0.78	0.53	0.34	0.65	0.76
Common Stock Total Equity	-0.63	-0.47	-0.48	-0.49	-0.67	-0.59	0.29	0.48	-0.49	-0.41	-0.53	-0.67	-0.5		-0.66	-0.45	-0.65	-0.44	-0.67	-0.48	1.0	-0.69	-0.47	-0.17	-0.54	-0.57
Common Stock Shares Outstanding	0.89	0.79	0.8	0.8	0.86	0.69	-0.35	-0.68	0.76	0.58	0.8	0.9	0.8	-0.66		0.74	0.98	0.78	0.91	0.62	-0.66	0.91	0.71	0.37	0.83	0.88
Other Current Assets	0.75	0.88	0.98	0.98	0.65	0.36	-0.07	-0.88	0.91	0.41	0.76	0.66	0.63	-0.45	0.74		0.8	0.8	0.69	0.88	-0.45	0.76	0.39	0.41	0.58	0.95
Other Stockholder Equity	0.92	0.87	0.86	0.86	0.87	0.67	-0.32	-0.73	0.83	0.58	0.85	0.9	0.82	-0.65	0.98	0.8		0.85	0.91	0.69	-0.65	0.94	0.67	0.39	0.84	0.91
Total Liab	0.89	0.98	0.9	0.89	0.73	0.5	-0.51	-0.63	0.77	0.78	0.84	0.84	0.83	-0.44	0.78	0.8	0.85		0.86	0.62	-0.44	0.77	0.42	0.5	0.53	0.87
Total Current Assets	0.96	0.81	0.79	0.78	0.93	0.7	-0.61	-0.56	0.68	0.81	0.84	1.0	0.9	-0.67	0.91	0.69	0.91	0.86		0.52	-0.67	0.92	0.72	0.45	0.72	0.85
Short Term Debt	0.53	0.76	0.84	0.86	0.42	0.14	0.26	-0.97	0.95	0.09	0.5	0.49	0.49	-0.48	0.62	0.88	0.69	0.62	0.52		-0.48	0.57	0.3	-0.04	0.65	0.79
Common Stock	-0.63	-0.47	-0.48	-0.49	-0.67	-0.59	0.29	0.48	-0.49	-0.41	-0.53	-0.67	-0.5	1.0	-0.66	-0.45	-0.65	-0.44	-0.67	-0.48		-0.69	-0.47	-0.17	-0.54	-0.57
Net Tangible Assets	0.95	0.78	0.8	0.8	0.96	0.74	-0.42	-0.6	0.7	0.64	0.91	0.92	0.78	-0.69	0.91	0.76	0.94	0.77	0.92	0.57	-0.69		0.74	0.54	0.76	0.88
Non Currrent Assets Other	0.68	0.39	0.44	0.43	0.77	0.46	-0.33	-0.3	0.41	0.42	0.58	0.74	0.53	-0.47	0.71	0.39	0.67	0.42	0.72	0.3	-0.47	0.74		0.21	0.78	0.53
Other Assets	0.61	0.43	0.46	0.42	0.6	0.59	-0.62	0.04	0.12	0.67	0.73	0.45	0.34	-0.17	0.37	0.41	0.39	0.5	0.45	-0.04	-0.17	0.54	0.21		-0.04	0.5
Short Term Investments	0.68	0.59	0.6	0.63	0.69	0.5	0.02	-0.66	0.74	0.2	0.57	0.71	0.65	-0.54	0.83	0.58	0.84	0.53	0.72	0.65	-0.54	0.76	0.78	-0.04		0.66
Inventory	0.89	0.91	0.98	0.97	0.81	0.56	-0.29	-0.81	0.88	0.59	0.86	0.84	0.76	-0.57	0.88	0.95	0.91	0.87	0.85	0.79	-0.57	0.88	0.53	0.5	0.66

Click cells to compare fundamentals

Regenxbio Account Relationship Matchups

Regenxbio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	497.9M	708.2M	1.1B	833.3M	574.0M	487.0M
Short Long Term Debt Total	11.3M	72.7M	86.7M	94.8M	89.3M	50.0M
Other Current Liab	21.5M	62.2M	100.9M	89.4M	93.2M	97.9M
Total Current Liabilities	33.7M	81.4M	130.5M	130.4M	130.3M	136.8M
Total Stockholder Equity	450.2M	377.8M	764.3M	516.2M	311.7M	348.3M
Net Debt	(58.2M)	(265.8M)	(258.5M)	(2.2M)	54.8M	57.5M
Retained Earnings	(177.8M)	(289.1M)	(161.2M)	(441.6M)	(705.0M)	(669.8M)
Accounts Payable	6.4M	10.6M	11.4M	27.2M	22.8M	23.9M
Cash	69.5M	338.4M	345.2M	97.0M	34.5M	32.8M
Non Current Assets Total	152.9M	177.0M	595.1M	417.3M	239.0M	200.1M
Cash And Short Term Investments	296.2M	475.7M	457.4M	364.6M	275.3M	255.6M
Net Receivables	38.1M	43.0M	32.4M	28.1M	26.3M	18.3M
Common Stock Shares Outstanding	36.7M	37.3M	43.9M	43.2M	43.7M	33.3M
Liabilities And Stockholders Equity	497.9M	708.2M	1.1B	833.3M	574.0M	487.0M
Other Current Assets	4.2M	12.5M	28.9M	23.3M	33.4M	35.0M
Other Stockholder Equity	627.8M	667.2M	928.1M	973.1M	1.0B	551.6M
Total Liab	47.7M	330.4M	349.6M	317.1M	262.2M	138.7M
Total Current Assets	345.0M	531.2M	518.8M	416.0M	335.0M	286.9M
Accumulated Other Comprehensive Income	205K	(360K)	(2.6M)	(15.4M)	(4.4M)	(4.2M)
Net Tangible Assets	450.2M	377.8M	764.3M	516.2M	593.6M	386.3M
Non Currrent Assets Other	10.0M	9.9M	10.7M	9.9M	7.5M	8.4M
Other Assets	10.0M	8.8M	1.1B	9.9M	11.4M	10.8M
Short Term Investments	226.7M	137.3M	112.2M	267.7M	240.7M	168.1M
Inventory	6.5M	10.5M	18.8M	13.9M	16.0M	16.8M
Long Term Investments	103.8M	50.1M	394.2M	200.6M	38.9M	36.9M
Property Plant Equipment	39.1M	56.5M	192.5M	206.8M	237.8M	249.7M
Other Liab	5.2M	178.8M	134.2M	97.8M	112.5M	58.5M
Property Plant And Equipment Net	39.1M	120.3M	192.5M	206.8M	192.6M	98.2M
Retained Earnings Total Equity	(83.0M)	(177.8M)	(289.1M)	(161.2M)	(145.1M)	(152.4M)
Non Current Liabilities Total	14.0M	249.0M	219.1M	186.6M	132.0M	99.8M
Capital Surpluse	592.6M	627.8M	667.2M	928.1M	1.1B	586.6M
Property Plant And Equipment Gross	39.1M	120.3M	192.5M	206.8M	249.8M	262.3M
Net Invested Capital	450.2M	377.8M	764.3M	516.2M	311.7M	489.0M
Net Working Capital	311.4M	449.8M	388.4M	285.5M	204.7M	331.4M
Capital Lease Obligations	11.3M	72.7M	86.7M	94.8M	89.3M	66.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Regenxbio Stock Analysis

When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regenxbio Research Development vs Reconciled Depreciation Analysis

Research Development vs Reconciled Depreciation

Research Development vs Reconciled Depreciation Correlation Analysis

Correlation Coefficient

Research Development

Reconciled Depreciation

Regenxbio fundamental ratios Correlations

Regenxbio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regenxbio fundamental ratios Accounts

Also Currently Popular

Additional Tools for Regenxbio Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Other Current Liab
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 0.98	Short Long Term Debt Total
Other Current Assets	+ 0.98	Other Current Liab
Inventory	+ 0.98	Other Current Liab

Short Term Debt	- 0.97	Retained Earnings
Accounts Payable	- 0.93	Retained Earnings
Cash	- 0.93	Net Debt
Other Current Assets	- 0.88	Retained Earnings
Retained Earnings	- 0.85	Total Current Liabilities
Retained Earnings	- 0.83	Other Current Liab